Assessment of seroprevalence against poliovirus among Italian adolescents and adults

References

• World Health Organization (WHO). Polio vaccines: WHO position paper. Wkly Epidemiol Rec. 2016;91(12):145–168.
   PubMedGoogle Scholar
• Sutter RW, Pallansch MA, Sawyer LA, Cochi SL, Hadler SC. Defining surrogate serologic tests with respect to predicting protective vaccine efficacy: poliovirus vaccination. Ann N Y Acad Sci. 754;1995:289–299.
   PubMed Web of Science ®Google Scholar
• Sutter RW, Kew OM, Cochi SL, Aylward RB. Poliovirus vaccine-live. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. Philadelphia, PA: Elsevier-Saunders; 2017. p. 866–917.
   Google Scholar
• Global Polio Eradication Initiative. [ Accessed 2018 Feb 2]. http://polioeradication.org/where-we-work/polio-endemic-countries/
   Google Scholar
• Tafuri S, Prato R, Martinelli D, Calvario A, Bozzi A, Labianca M, Patti A, Lopalco PL, Germinario C. Serological survey on immunity status against polioviruses in children and adolescents living in a border region, Apulia (Southern Italy). BMC Infect Dis. 2008;8:.150. doi:10.1186/1471-2334-8-150.
   PubMed Web of Science ®Google Scholar
• Majori S, Baldo V, Poli A, Riolfatti M, Alborino F, Bonello C, Frau S, Baldovin T, Dal Zotto A, Romano G, et al. Immunity to poliovirus among children and the elderly in north-east Italy. J Prev Med Hyg. 2006;47(1):12–15.
   PubMedGoogle Scholar
• Baldo V, Baldovin T, Cocchio S, Lazzari R, Saracino E, Bertoncello C, Buja A, Trevisan A. Seroepidemiology of polioviruses among university students in northern Italy. Clin Vaccine Immunol. 2012;19(8):1292–1295. doi:10.1128/CVI.00054-12.
   PubMed Web of Science ®Google Scholar
• Conferenza permanente per i rapporti tra lo Stato, le Regioni e le Province Autonome di Trento e Bolzano. Accordo tra il Ministero della Salute, le Regioni e le Province Autonome di Trento e Bolzano sulle modifiche al calendario della vaccinazione antipoliomielitica; 2002 May 30. [Italian]. 10.1044/1059-0889(2002/er01)
   Google Scholar
• European Centre for Disease Prevention and Control. Wild-type poliovirus 1 transmission in Israel – what is the risk to the EU/EEA? Stockholm, Sweden: ECDC; 2013. [ Accessed 2018 Mar 2]. http://ecdc.europa.eu/en/publications/Publications/polio-risk-assessment-transmission-in-Israel.pdf
   Google Scholar
• Wallace GS, Curns AT, Weldon WC, Oberste MS. Seroprevalence of poliovirus antibodies in the United States population, 2009-2010. BMC Public Health. 2016;16:.721. doi:10.1186/s12889-016-3386-1.
   PubMed Web of Science ®Google Scholar
• Reinheimer C, Friedrichs I, Rabenau HF, Doerr HW. Deficiency of immunity to poliovirus type 3: a lurking danger? BMC Infect Dis. 2012;12:.24. doi:10.1186/1471-2334-12-24.
   PubMed Web of Science ®Google Scholar
• Frantzidou F, Diza E, Halkia D, Antoniadis A. A seroprevalence study of poliovirus antibody in the population of northern Greece. Clin Microbiol Infect. 2005;11(1):68–71. doi:10.1111/j.1469-0691.2004.00998.x.
   PubMed Web of Science ®Google Scholar
• Pires de Miranda M, Carmo Gomes M, Rebelo de Andrade H. Seroprevalence of antibodies to poliovirus in individuals living in Portugal, 2002. Euro Surveill. 2007;12(6):E7–E8.
   PubMedGoogle Scholar
• van der Maas NA, Mollema L, Berbers GA, van Rooijen DM, van der Avoort HG, Conyn-Van Spaendonck MA, de Melker HE, van der Klis FR. Immunity against poliomyelitis in the Netherlands, assessed in 2006 to 2007: the importance of completing a vaccination series. Euro Surveill. 2014;19(7):20705. doi:10.2807/1560-7917.ES2014.19.7.20705.
   PubMedGoogle Scholar
• Martin N, Paterson BJ, Durrheim DN. Australia’s polio risk. Commun Dis Intell Q Rep. 2014;38(2):E107–13.
   PubMedGoogle Scholar
• Wallace GS, Pahud BA, Weldon WC, Curns AT, Oberste MS, Harrison CJ. Seroprevalence of poliovirus antibodies in the Kansas City metropolitan area, 2012-2013. Hum Vaccin Immunother. 2017;13(4):776–783. doi:10.1080/21645515.2016.1255386.
   PubMed Web of Science ®Google Scholar
• Roivainen M, Montagnon B, Chalumeau H, Murray M, Wimmer E, Hovi T. Improved distribution of antigenic site specificity of poliovirus-neutralizing antibodies induced by a protease-cleaved immunogen in mice. J Virol. 1990;64(2):559–562.
   PubMed Web of Science ®Google Scholar
• Nijsten D, Carrillo-Santisteve P, Miglietta A, Ruitenberg J, Lopalco PL. Is EU/EEA population protected from polio? Hum Vaccin Immunother. 2015;11(9):2123–2131. doi:10.1080/21645515.2015.1016673.
   PubMed Web of Science ®Google Scholar
• Veronesi L, Affanni P, Verrotti Di Pianella C, Colucci ME, Tanzi ML. Immunity status against poliomyelitis in childbearing women in a province of northern Italy. A cross-sectional analysis. Ann Ig. 2013;25:427–433. doi:10.7416/ai.2013.1944.
   PubMedGoogle Scholar
• Ministero della Salute. Piano Nazionale della Prevenzione Vaccinale 2017-2019. G.U. Serie Generale, n. 41 del 18 febbraio 2017 [Italian].
   Google Scholar
• De Donno A, Kuhdari P, Guido M, Rota MC, Bella A, Brignole G, Lupi S, Idolo A, Stefanati A, Del Manso M, et al. Study Group on seroepidemiology. Has VZV epidemiology changed in Italy? Results of a seroprevalence study. Hum Vaccin Immunother. 2017;13(2):385–390. doi:10.1080/21645515.2017.1264828.
   PubMed Web of Science ®Google Scholar
• Foiadelli T, Savasta S, Battistone A, Kota M, Passera C, Fiore S, Bino S, Amato C, Lozza A, Marseglia GL, et al. Nucleotide variation in Sabin type 3 poliovirus from an Albanian infant with agammaglobulinemia and vaccine associated poliomyelitis. BMC Infect Dis. 2016;16:277. doi:10.1186/s12879-016-1587-y.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Polio laboratory manual. 4th ed. Geneva, Switzerland: WHO/IVB/04.10; 2004.
   Google Scholar
• World Health Organization (WHO). Manual for the virological investigation of polio. Geneva, Switzerland: WHO/EPI/GEN/97.01; 1997.
   Google Scholar